同源重组缺陷状态对一线铂类化疗后晚期上皮性卵巢癌患者的预后和预测价值数据表

数据集获取（Figshare）

• 源站标题：DataSheet_1_The prognostic and predictive value of homologous recombination deficiency status in patients with advanced stage epithelial ovarian carcinoma after first-line platinum-based chemotherapy.docx
• DOI：10.3389/fonc.2024.1372482.s001
• 发布日期：2024-06-10
• 文件数：1 个
• 文件总体积：23.27 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_The_prognostic_and_predictive_value_of_homologous_recombination_deficiency_status_in_patients_with_advanced_stage_epithelial_ovarian_carcinoma_after_first-line_platinum-based_chemotherapy_docx/26000305

命令行下载

curl -L -o "DataSheet_1_The prognostic and predictive value of homologous recombination deficiency status in patients with advanced stage epithelial ovarian carci.docx" "https://ndownloader.figshare.com/files/46943863"

文件清单

• DataSheet_1_The prognostic and predictive value of homologous recombination deficiency status in patients with advanced stage epithelial ovarian carci.docx（23.27 KB）

文件总体积 23.27 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ObjectiveHomologous recombination (HR) comprises series of interrelated pathways that repair double-stranded DNA breaks and inter-strand crosslinks. It provides support for DNA replication to recover stalled or broken replication forks. Compared with homologous recombination proficiency (HRP), cancers with homologous recombination deficiency (HRD) are more likely to undergo cell death when treated with DNA-damaging agents, such as platinum agents, and have better disease control.
MethodsPatients diagnosed with stage III/IV ovarian cancer, early stages with recurrence, who received adjuvant chemotherapy after debulking surgery, and who also had known HR status were eligible.
ResultsForty-four patients were included, with 21 in the HRD group (including 8 with germline mutations) and 23 in the HRP group. The HRD group was composed predominantly of serous carcinoma (95.2%), while mucinous (n=3) and clear cell (n=1) cases were all found in the HRP group. Stage III/IV disease was 66.7% and 91.3% in HRD and HRP groups, respectively (p=0.064). Patients who were optimally debulked to no residual disease was 90.0% and 72.7% (p=0.243), respectively. Late line use of PARP inhibitors was 33.3% and 17.4% (p=0.303). Median PFS was 22.5 months (95% CI, 18.5 - 66.6) and 21.5 months (95% CI, 18.3-39.5) (p=0.49) in HRD and HRP respectively. Median platinum free interval (PFI) was 15.8 months (95% CI 12.4-60.4) and 15.9 months (95% CI 8.3-34.1) (p=0.24), respectively. Median OS was 88.2 months (95% CI 71.2-NA) and 49.7 months (95% CI 35.1-NA) (p=0.21). The PFS of the patients with germline BRCA mutations (n=5) was 54.3 months (95% CI 23.1-NA) and 21.5 months (95% CI 18.3-39.5) in the HRP group (p=0.095); the PFI difference was 47.7 months (95% CI 17.6-NA) in the BRCA mutation group, and 15.9 months (95% CI 12.4-60.4) in HRP, showing statistical significance (p=0.039); while the median OS was NA and 49.7 months (95% CI 35.1-NA) respectively (p=0.051). When adding two additional patients with somatic BRCA mutations to the germline BRCA mutation carriers, the median OS is NA (95% CI 73, NA) versus 49.7 months (95% CI 35.1, NA) for HRP (p=0.045).
ConclusionsHRD status was not associate

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2024.1372482.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_The_prognostic_and_predictive_value_of_homologous_recombination_deficiency_status_in_patients_with_advanced_stage_epithelial_ovarian_carcinoma_after_first-line_platinum-based_chemotherapy_docx/26000305）。